Literature DB >> 9666918

The diurnal variation of intraocular pressure in non-glaucomatous subjects: relevance in a clinical context.

J S Pointer.   

Abstract

Although it has been recognised for a century that an individual's intraocular pressure (i.o.p.) varies over a 24 hr period, the implications for the clinician of this physiological characteristic remain uncertain. While financial constraints nowadays prohibit in-patient assessment of suspect ocular hypertensive cases, the U.K. has witnessed a concurrent increase in the monitoring of at-risk subjects at local centres, including optometric practices. Consequently a description of the pattern of variation of IOP in the at-risk population during normal consulting hours, assessed using a popular model of pneumo-applanation tonometer, could assist the clinician in establishing management and referral protocols. This report describes the results of a single-centre study based on the retrospective analysis of the records of over 1,500 age-matched male and female at-risk but assumed non-glaucomatous subjects. Statistical analysis of the collated data indicated that subject age group was not a major variable: however gender and the time of IOP assessment were both significant features. For recordings between the hours of 09.00 and 18.00 human non-glaucomatous males and females registered an IOP peak in the late morning, succeeded by a lowered value from mid-afternoon. For both male age groups (40-59 and 60+ years) the afternoon mean IOP values were significantly lower than the male morning values and significantly different to the female morning and afternoon means. On the basis of these results it is suggested that male subjects who record borderline or high pressures at an afternoon appointment should be reassessed the following (mid-)morning; also that subsequent reviews of such cases should be scheduled for morning visits. By adopting this approach the likelihood of recording an elevated IOP value is increased and true-positive cases of raised IOP identified. However, during normal consulting hours the present evidence suggests that this temporal precaution need not be observed in female subjects.

Entities:  

Mesh:

Year:  1997        PMID: 9666918

Source DB:  PubMed          Journal:  Ophthalmic Physiol Opt        ISSN: 0275-5408            Impact factor:   3.117


  7 in total

1.  Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Authors:  D Wong; I Campbell; C Groenwald; E Lancaster
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

2.  South African Eye Study (SAES): ethnic differences in central corneal thickness and intraocular pressure.

Authors:  S O Baboolal; D P Smit
Journal:  Eye (Lond)       Date:  2018-01-12       Impact factor: 3.775

Review 3.  Systemic hypertension, headache, and ocular hemodynamics: a new hypothesis.

Authors:  Vinod Kumar Gupta
Journal:  MedGenMed       Date:  2006-09-12

4.  Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells.

Authors:  Juanita Dortch-Carnes; Gianluca Tosini
Journal:  Exp Eye Res       Date:  2012-11-29       Impact factor: 3.467

5.  Estimating the long-term visual field consequences of average daily intraocular pressure and variance : a clinical trial comparing timolol, latanoprost and travoprost.

Authors:  J P Nordmann; C Lepen; H Lilliu; G Berdeaux
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

6.  Biofluid modeling of the coupled eye-brain system and insights into simulated microgravity conditions.

Authors:  Fabrizia Salerni; Rodolfo Repetto; Alon Harris; Peter Pinsky; Christophe Prud'homme; Marcela Szopos; Giovanna Guidoboni
Journal:  PLoS One       Date:  2019-08-14       Impact factor: 3.240

7.  Diurnal variation in central corneal thickness and intraocular pressure in eyes with pseudoexfoliation syndrome without glaucoma.

Authors:  Stuart Keel; Linda Malesic; Siew-Pang Chan
Journal:  Indian J Ophthalmol       Date:  2014-11       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.